Aquestive Therapeutics
Update in progressAQST (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Aquestive Therapeutics, Inc. is a Warren, New Jersey-based pharmaceutical company focused on advanced drug delivery. It offers Libervant (buccal diazepam) for seizures; Suboxone (buprenorphine/naloxone) sublingual film for opioid dependence; EMYLIF, ONDIF, and SYMPAZAN films for epilepsy and seizures; KYNMOBI (apomorphine) and AZSTARYS (ADHD, 6+). Its pipeline includes Anaphylm (epinephrine sublingual film) in Phase 3 and AQST-108 topical gel in Phase 2, plus PharmFilm and Adrenaverse technologies.
Company score
- Sentiment
- 0.04
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.03
- Governance
- -0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.00
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.02
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMr. Daniel Barber
- Founded2004
- Employees147
- Websitewww.aquestive.com
Identifiers
- ISINUS03843E1047
- FIGIBBG00L9HP0Z0
- CUSIP03843E104
- CIK0001398733